DIAGNOSTIC VALUE OF STIMULATED SERUM THYROGLOBULIN IN THE FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.For differentiated thyroid cancer (DTC) patients with initially negative stimulated serum thyroglobulin (sTg) tests, repeated sTg measurements offer limited additional benefit. Annual sTg testing is not recommended for routine follow-up in low- and intermediate-risk DTC cases.
Area Of Science
- Endocrinology
- Oncology
- Nuclear Medicine
Background
- Differentiated thyroid cancer (DTC) requires long-term monitoring for recurrence.
- Stimulated serum thyroglobulin (sTg) is a key biomarker for DTC follow-up.
- The utility of repeated sTg measurements after an initial negative result needs clarification.
Purpose Of The Study
- To assess the diagnostic value of stimulated serum thyroglobulin (sTg) in DTC patient follow-up.
- To determine if repeated sTg measurements provide additional clinical benefit in detecting persistent or recurrent disease after an initial negative sTg.
Main Methods
- Retrospective study of 388 DTC patients treated between 2004 and 2018.
- Comparison of the negative predictive value (NPV) of the first sTg (12 months post-treatment) with annual sTg measurements over 3 years.
- Analysis stratified by low- and intermediate-risk patient groups.
Main Results
- The first sTg measurement showed high NPV (99.5% for low-risk, 96.1% for intermediate-risk).
- No significant difference in NPV was observed between the first sTg and annual measurements over 3 years for either risk group.
- Repeated sTg measurements after an initial negative result had limited value in detecting structural disease.
Conclusions
- Initial stimulated serum thyroglobulin (sTg) measurement is highly effective in ruling out persistent or recurrent disease in low- and intermediate-risk DTC patients.
- Routine annual sTg testing beyond the initial 12-month assessment is not recommended for these patient groups.
- Current follow-up protocols for low- and intermediate-risk DTC may be streamlined by focusing on the initial post-treatment sTg assessment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...